Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27

Molecular and Cellular Biology

Volumn 25, Issue 11, 2005, Pages 4565-4578

  Mack, Fiona A ^a,b   Patel, Jagruti H ^b   Biju, Mangatt P ^b   Haase, Volker H ^b   Simon, M Celeste ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENERGY METABOLISM; FIBROSARCOMA; GENE MUTATION; GENE SILENCING; GENETIC PREDISPOSITION; HEMATOPOIESIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EMBRYO; FEMALE; FIBROBLASTS; FIBROSARCOMA; GENE SILENCING; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, MUTANT STRAINS; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 18944376218     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.11.4565-4578.2005     Document Type: Article

References (42)

1. Arsham, A. M., D. R. Plas, C. B. Thompson, and M. C. Simon. 2002. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem. 277:15162-15170.
2. Baba, M., S. Hirai, H. Yamada-Okabe, K. Hamada, H. Tabuchi, K. Kobayashi, K. Kondo, M. Yoshida, A. Yamashita, T. Kishida, N. Nakaigawa, Y. Nagashima, Y. Kubota, M. Yao, and S. Ohno. 2003. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22:2728-2738.
3. CIP1 via Cdc42/Racl signaling. Mol. Cell. Biol. 22:4587-4597.
4. Bindra, R. S., J. R. Vasselli, R. Stearman, W. M. Linehan, and R. D. Klausner. 2002. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62:3014-3019.
5. Blouw, B., H. Song, T. Tihan, J. Bosze, N. Ferrara, H. P. Gerber, R. S. Johnson, and G. Bergers. 2003. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4:133-146.
6. Bruick, R. K. 2000. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97:9082-9087.
7. Foster, K., A. Prowse, A. van den Berg, S. Fleming, M. M. Hulsbeek, P. A. Crossey, F. M. Richards, P. Cairns, N. A. Affara, M. A. Ferguson-Smith, et al. 1994. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3:2169-2173.
8. Gardner, L. B., Q. Li, M. S. Park, W. M. Flanagan, G. L. Semenza, and C. V. Dang. 2001. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276:7919-7926.
9. Gnarra, J. R., D. R. Duan, Y. Weng, J. S. Humphrey, D. Y. Chen, S. Lee, A. Pause, C. F. Dudley, F. Latif, I. Kuzmin, L. Schmidt, F. M. Duh, T. Stackhouse, F. Chen, T. Kishida, M. H. Wei, M. I. Lennan, B. Zbar, R. D. Klausner, and W. M. Linehan. 1996. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim. Biophys. Acta 1242:201-210.
10. Gnarra, J. R., J. M. Ward, F. D. Porter, J. R. Wagner, D. E. Devor, A. Grinberg, M. R. Emmert-Buck, H. Westphal, R. D. Klausner, and W. M. Linehan. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94:9102-9107.
11. Goda, N., H. E. Ryan, B. Khadivi, W. McNulty, R. C. Rickert, and R. S. Johnson. 2003. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:359-369.
12. Kip1 regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell. Biol. 21:1196-1206.
13. Haase, V. H., J. N. Glickman, M. Socolovsky, and R. Jaenisch. 2001. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA 98:1583-1588.
14. Hergovich, A., J. Lisztwan, R. Barry, P. Ballschmieter, and W. Krek. 2003. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5:64-70.
15. Iliopoulos, O., A. Kibel, S. Gray, and W. G. Kaelin. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
16. Iliopoulos, O., A. P. Levy, C. Jiang, W. G. Kaelin, Jr., and M. A. Goldberg. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93:10595-10599.
17. Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin, Jr. 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464-468.
18. Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472.
19. Johnson, R., B. Spiegelman, D. Hanahan, and R. Wisdom. 1996. Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell. Biol. 16:4504-4511.
20. Kamada, M., K. Suzuki, Y. Kato, H. Okuda, and T. Shuin. 2001. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 61:4184-4189.
21. Kondo, K., W. Y. Kim, M. Lechpammer, and W. G. Kaelin, Jr. 2003. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1:E83.
22. Kondo, K., J. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin, Jr. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246.
23. Koshiji, M., Y. Kageyama, E. A. Pete, I. Horikawa, J. C. Barrett, and L. E. Huang. 2004. HIF-1alpha induces cell cycle arrest by functionally counter-acting Myc. EMBO J. 23:1949-1956.
24. Kozma, L., I. Kiss, A. Nagy, S. Szakall, and I. Ember. 1997. Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett. 111:127-131.
25. Krieg, M., R. Haas, H. Brauch, T. Acker, I. Flamme, and K. H. Plate. 2000. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443.
26. Mack, F. A., W. K. Rathmell, A. M. Arsham, J. Gnarra, B. Keith, and M. C. Simon. 2003. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3:75-88.
27. Maher, E. R., and W. G. Kaelin, Jr. 1997. von Hippel-Lindau disease. Medicine (Baltimore) 76:381-391.
28. Maltepe, E., B. Keith, A. M. Arsham, J. R. Brorson, and M. C. Simon. 2000. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem. Biophys. Res. Commun. 273:231-238.
29. Maltepe, E., J. V. Schmidt, D. Baunoch, C. A. Bradfield, and M. C. Simon. 1997. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403-407.
30. Mandriota, S. J., K. J. Turner, D. R. Davies, P. G. Murray, N. V. Morgan, H. M. Sowter, C. C. Wykoff, E. R. Maher, A. L. Harris, P. J. Ratcliffe, and P. H. Maxwell. 2002. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468.
31. Maranchie, J. K., J. R. Vasselli, J. Riss, J. S. Bonifacino, W. M. Linehan, and R. D. Klausner. 2002. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255.
32. Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
33. Ohh, M., R. L. Yauch, K. M. Lonergan, J. M. Whaley, A. O. Stemmer-Rachamimov, D. N. Louis, B. J. Gavin, N. Kley, W. G. Kaelin, Jr., and O. Iliopoulos. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1:959-968.
34. Okuda, H., K. Saitoh, S. Hirai, K. Iwai, Y. Takaki, M. Baba, N. Minato, S. Ohno, and T. Shuin. 2001. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276:43611-43617.
35. Park, S. K., A. M. Dadak, V. H. Haase, L. Fontana, A. J. Giaccia, and R. S. Johnson. 2003. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1 α (HIF-1α): role of cytoplasmic trapping of HIF-2α. Mol. Cell. Biol. 23:4959-4971.
36. Pause, A., S. Lee, K. M. Lonergan, and R. D. Klausner. 1998. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA 95:993-998.
37. Pfander, D., T. Kobayashi, M. C. Knight, E. Zelzer, D. A. Chan, B. R. Olsen, A. J. Giaccia, R. S. Johnson, V. H. Haase, and E. Schipani. 2004. Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development 131:2497-2508.
38. Schipani, E., H. E. Ryan, S. Didrickson, T. Kobayashi, M. Knight, and R. S. Johnson. 2001. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 15:2865-2876.
39. Sowter, H. M., P. J. Ratcliffe, P. Watson, A. H. Greenberg, and A. L. Harris. 2001. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:6669-6673.
40. Wykoff, C. C., C. Sotiriou, M. E. Cockman, P. J. Ratcliffe, P. Maxwell, E. Liu, and A. L. Harris. 2004. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90:1235-1243.
41. Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630-9635.
42. Zimmer, M., D. Doucette, N. Siddiqui, and O. Iliopoulos. 2004. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol. Cancer Res. 2:89-95.